Core Scientific (CORZZ) Cash from Financing Activities (2021 - 2026)

Core Scientific's Cash from Financing Activities history runs 6 years deep, the most recent figure standing at $971.4 million for Q1 2026.

• In Q1 2026, Cash from Financing Activities rose 23239.16% year-over-year to $971.4 million; the TTM figure through Mar 2026 stood at $912.5 million (up 19.9% YoY), while the FY2025 annual figure was -$63.1 million, down 107.7% from the prior year.
• Cash from Financing Activities came in at $971.4 million for Q1 2026 at Core Scientific, up from -$21.8 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $971.4 million in Q1 2026 to a low of -$45.1 million in Q3 2022.
• A 5-year average of $117.0 million and a median of -$4.2 million in 2025 frame the typical range for Cash from Financing Activities.
• Across the five-year window, Cash from Financing Activities plunged 148.04% in 2023 and surged 23239.16% in 2026, its largest moves.
• Core Scientific's Cash from Financing Activities stood at $38.1 million in 2022, then slumped by 148.04% to -$18.3 million in 2023, then surged by 3369.23% to $598.2 million in 2024, then tumbled by 103.65% to -$21.8 million in 2025, then soared by 4554.25% to $971.4 million in 2026.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered $971.4 million, -$21.8 million, and -$5.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison